Download a hi-res photo
Sara Radcliffe is the Executive Vice President for Health at the Biotechnology Industry Organization (BIO). In that role, Ms. Radcliffe has responsibility for identifying, developing and implementing strategic BIO approaches to improving the ability of BIO's human healthcare focused companies to research and develop life-saving and life-enhancing biotechnology products, and to bring these products to market. Among the priorities of BIOs Health are: promoting a science-based FDA regulatory environment, enhancing patient access to innovative therapies and vaccines through reimbursement systems that recognize the value of biotechnology products, ensuring that biosimilars policies protect patient safety and promote innovation, and securing support for policies that advance personalized medicine and emergency preparedness. Prior to joining BIO, Ms. Radcliffe served as Senior Director, Biologics & Biotechnology at the Pharmaceutical Research and Manufacturers of America (PhRMA). She also served in the Alliance and Technology Group at SmithKline Beecham Pharmaceuticals as a Research and Development Policy Analyst, working on evaluation and communication of the promise, ethics, and impact of rapidly-developing technologies in DNA Research. In addition she worked for the Core Services Committee of the New Zealand Ministry of Health. Ms. Radcliffe holds a Master of Public Health and a Master of Arts in Philosophy from the Johns Hopkins University.